Tom Logan, PhD, was hired as Senior Executive Director of Business Development within the Office of the Chief Innovation Officer (OCINO) in 2025. Reporting directly to the Chief Innovation Officer, the Senior Executive Director of Business Development supports oversight of all activities and initiatives of the Office of the Chief Innovation Officer (OCINO), with responsibility for business development, fund management and technology acceleration efforts being led on behalf of the University by the OCINO. The Senior Executive Director works towards strengthening the interactions between Penn (and its twelve schools) and external partners in the areas of research and development, technology translation, new business creation, incubation and funding initiatives, and commercialization. By helping to facilitate these types of strategic partnerships, the Senior Executive Director is responsible for delivering valuable new technologies and business opportunities for the University of Pennsylvania.
About Tom
Tom Logan was previously the Chief Business Officer for the Penn Gene Therapy Program (GTP) where he oversaw the business development, alliance management, finance and legal functions. Tom played a key role in leading the 2024 spin out of GTP into the independent companies Gemma Biotherapeutics and Franklin Biolabs.
Prior to joining Penn in 2019, Tom held a variety of R&D and business development leadership positions in the UK pharmaceutical and medical device company BTG which was acquired by Boston Scientific, Millennium Pharmaceuticals (Takeda), and Rhone Poulenc Rorer (Sanofi). Tom completed a cardiovascular drug discovery post-doctoral fellowship at GSK and received his PhD in Biochemistry and Molecular Biology from Thomas Jefferson University. Outside of work, Tom is active in the community serving on the boards of various non-profit organizations and area high schools and enjoys spending time with his family, wife Regina and their five children and first grandchild.